Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
11 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250611109903/en/Capsida-Receives-FDA-IND-Clearance-for-Its-IV-Administered-Gene-Therapy-for-Parkinsons-Disease-Associated-With-GBA-Mutations
29 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250529358091/en/Capsida-Receives-FDA-Fast-Track-Designation-for-Its-Potential-First-in-Class-IV-Administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy
14 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250514208408/en/Capsida-Presents-New-GLP-Toxicology-Data-Supporting-Recent-FDA-IND-Clearance-of-Its-First-in-Class-IV-administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy
12 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250512366164/en/Capsida-Receives-FDA-IND-Clearance-for-Its-First-in-Class-IV-administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy
28 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250428763273/en/Capsida-to-Present-Progress-Updates-at-the-ASGCT-Annual-Meeting-Including-NHP-GLP-Toxicology-Study-Results-for-its-Potential-First-in-Class-STXBP1-Developmental-and-Epileptic-Encephalopathy-Program-CAP-002-STXBP1-DEE
03 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/capsida-presents-new-data-from-glp-toxicology-study-in-nhps-demonstrating-potential-best-in-class-profile-of-cap-003-in-patients-with-parkinsons-disease-associated-with-gba-mutations-pd-gba-302417461.html
ABOUT THIS PAGE